---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000111"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:39:45.028660+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics effects 1-for-15 reverse stock split effective Jan 31, 2024

## Summary
- Reverse stock split at a ratio of 1-for-15, effective January 31, 2024 at 5:00 p.m. ET.
- Every 15 pre-split shares converted into 1 share; par value unchanged at $0.001.
- Common stock continues trading on Nasdaq under symbol TCRT; new CUSIP 98973P200.
- Split ratio chosen by Board on Jan 12, 2024; stockholder authority granted at June 6, 2023 annual meeting.
- Equiniti Trust Company appointed as exchange agent for processing share conversions.

## SEC filing metadata
- accession: 0001193805-24-000111
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/0001193805-24-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/e619211_8k-at.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000111
- JSON: https://secwatch.observer/filing/0001193805-24-000111.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000111.txt

## Key facts
- Governance Changes
  Alaunos Therapeutics, Inc.: Filed a Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2024-01-31).
  - Change: charter amendment
  - Effective: 2024-01-31
  source text: On January 31, 2024, Alaunos Therapeutics, Inc. (the “Company”) filed a Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-15 (the “Reverse Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/0001193805-24-000111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.